Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)

SHE:002693 Revenue

Hainan Shuangcheng Pharmaceuticals had revenue of 68.72M CNY in the quarter ending June 30, 2026, with 44.83% growth. This brings the company's total for the last twelve months to 309.80M, up 89.55% year-over-year. In the year 2025, Hainan Shuangcheng Pharmaceuticals had annual revenue of 276.76M with 58.87% growth. That makes Hainan Shuangcheng Pharmaceuticals the 28,456th largest company in the world by revenue and 4,855th in China.

• Revenue (ttm): 309.80M
• Revenue Growth: +89.55%
• P/S Ratio: 12.14
• Revenue / Employee: 691.51K
• Employees: 448
• Market Cap: 3.76B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Production of drugs sales business 247.24M 71.7%
• Entrusted Business 92.00M 26.7%
• Other Business 5.78M 1.7%

By Geography

Chart

• Overseas Region 187.85M 67.9%
• East China 31.85M 11.5%
• Central China Region 20.46M 7.4%
• Southwest Region 19.18M 6.9%
• Southern China 9.54M 3.4%
• North China 3.22M 1.2%
• Northeast China Region 2.62M 0.9%
• Northwestern Region 2.04M 0.7%

Fiscal year ended Dec 31, 2025 See the full SHE:002693 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	276.76M	102.56M	58.87%
Dec 31, 2024	174.21M	-61.72M	-26.16%
Dec 31, 2023	235.93M	-38.82M	-14.13%
Jan 1, 2023	274.75M	-45.54M	-14.22%
Jan 1, 2022	320.29M	50.85M	18.87%

Data Source: S&P Global Market Intelligence Last updated: Aug 21, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error